SEARCH

Reuters Health News Summary

17 Oct 2020 / 13:00 H.

    Following is a summary of current health news briefs.

    Mexico's coronavirus death toll surpasses 85,700

    Mexico's health ministry on Friday reported 6,751 new confirmed cases of coronavirus infection and 419 additional fatalities, bringing the total in the country to 841,661 cases and 85,704 deaths. The government says the real number of infected people is likely significantly higher than the confirmed cases.

    'One-der-ful': Australia's coronavirus hotspot records single case

    Australia's coronavirus hotspot of Victoria recorded a single case of the disease on Saturday - the lowest daily number since early June - and no deaths, with the state's top health official saying the figures were "one-der-ful". Victoria's capital Melbourne, which has been the epicentre of the country's COVID-19 outbreak, is in its third month of a stringent lockdown and Premier Daniel Andrews is due to update plans to ease restrictions across the state on Sunday.

    U.S. CDC reports 216,917 deaths from coronavirus

    The U.S. Centers for Disease Control and Prevention (CDC) on Friday reported 7,958,254 cases of the new coronavirus, an increase of 63,486 from its previous count, and said that the number of deaths had risen by 892 to 216,917. The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Oct. 15 versus its previous report a day earlier.(https://bit.ly/3dz9fTp)

    Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint

    Investors betting on big profits from COVID-19 treatments may get an unwelcome surprise when Gilead Sciences Inc reports quarterly results this month. Its remdesivir, the first important coronavirus treatment, has not been used as much as first expected and faces complex insurance reimbursement issues. Its best hope may be that the United States and other Northern Hemisphere governments concerned about a winter spike in cases are beginning to stockpile the antiviral drug, which is also being tested in combination with experimental COVID-19 antibody therapies.

    Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

    Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. That timeline makes it unlikely, however, that a vaccine will be available before the U.S. election, as President Donald Trump has promised. Pfizer, which is developing the vaccine with German partner BioNTech, said that it may confirm if the vaccine is effective as soon as this month but that it also needs safety data from a 44,000-person clinical trial that will not be available until next month.

    Germany's confirmed coronavirus cases rise by 7,830 to 348,557: RKI

    The number of confirmed coronavirus cases in Germany increased by 7,830 to 348,557, data from the Robert Koch Institute (RKI) for infectious diseases showed on Saturday. The reported death toll rose by 33 to 9,734, the tally showed.

    Brazil registers 754 coronavirus deaths on Friday

    Brazil has registered 754 additional coronavirus deaths over the last 24 hours and 30,914 new confirmed cases, the nation's health ministry said on Friday. The South American country has now registered 153,214 total coronavirus deaths and 5.2 million total confirmed cases.

    COVID-19 cases surge in Wisconsin, Trump to campaign there

    Two weeks ago, Mark Schultz was getting ready to go to work at the tavern he owns in the Wisconsin city of Oshkosh when he started to feel sweaty, achy and chilled. Within days, the 64-year-old was in an intensive care unit at a local hospital fighting for his life.

    Row breaks out over WHO trial casting doubt on remdesivir as COVID-19 drug

    A row broke out on Friday over a World Health Organization (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient's chances of surviving COVID-19. Gilead Sciences Inc., the U.S. company that developed the drug, said the findings appeared inconsistent with evidence from other studies validating the clinical benefit of remdesivir, which was used to treat U.S. President Donald Trump's coronavirus infection.

    Remdesivir questioned by WHO trial; women take virus more seriously than men

    The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. Large WHO trial casts doubt on remdesivir and other drugs

    email blast